Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · IEX Real-Time Price · USD
17.32
+0.32 (1.88%)
At close: May 24, 2024, 4:00 PM
17.59
+0.27 (1.56%)
After-hours: May 24, 2024, 7:49 PM EDT
1.88%
Market Cap 908.86M
Revenue (ttm) n/a
Net Income (ttm) -75.45M
Shares Out 52.47M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,831
Open 17.16
Previous Close 17.00
Day's Range 17.32 - 17.32
52-Week Range 10.38 - 20.67
Beta 1.08
Analysts Strong Buy
Price Target 26.33 (+52.02%)
Earnings Date May 9, 2024

About TYRA

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and othe... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol TYRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price forecast is $26.33, which is an increase of 52.02% from the latest price.

Price Target
$26.33
(52.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tyra Biosciences to Present at Upcoming Investor Conferences

CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

4 days ago - PRNewsWire

Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights

- TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 - - Susa...

18 days ago - PRNewsWire

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S.

CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large...

20 days ago - PRNewsWire

Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights

- Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and dosed ...

2 months ago - PRNewsWire

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

3 months ago - PRNewsWire

Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing

CARLSBAD, Calif. , Feb. 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

4 months ago - PRNewsWire

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia

CARLSBAD, Calif. , Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

4 months ago - PRNewsWire

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

- Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200-  - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300- - Received FDA feedback on TYRA-300 Phas...

5 months ago - PRNewsWire

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference

CARLSBAD, Calif. , Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

7 months ago - PRNewsWire

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights

- Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patient to be dosed in TYRA-2...

7 months ago - PRNewsWire

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target la...

8 months ago - PRNewsWire

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target la...

9 months ago - PRNewsWire

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

-Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first patient to...

10 months ago - PRNewsWire

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

10 months ago - PRNewsWire

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...

1 year ago - PRNewsWire

Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights

-SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023- -Strong cash po...

1 year ago - PRNewsWire

Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights

-Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia- -Cleared IND for TYRA-200 Ph...

1 year ago - PRNewsWire

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024- -Conference call a...

1 year ago - PRNewsWire

Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif. , Nov. 29, 2022 /PRNewswire/ -- Tyra Bi...

1 year ago - PRNewsWire

Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights

-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif. , N...

1 year ago - PRNewsWire

Tyra Biosciences Announces Planned Chief Financial Officer Transition

-Esther van den Boom to transition to an advisor at year-end 2022- -Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif. , Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TY...

1 year ago - PRNewsWire

Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CARLSBAD, Calif. , Oct. 13, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...

1 year ago - PRNewsWire

Tyra Biosciences to Participate at September 2022 Investor Conferences

CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...

1 year ago - PRNewsWire

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...

1 year ago - PRNewsWire

Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights

-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 mill...

1 year ago - PRNewsWire